How Guardant Health is Supporting Cancer Care During the Pandemic. The following slide deck was published by Guardant Health, Inc. in conjunction with this event. Click to enlarge. Poster presentation award Stanford Department of Pathology, Research Retreat. Soon, it could detect cancer earlier than ever before. Guardant Health, Inc. 505 Penobscot Dr. Redwood City, CA 94063. Get the latest Guardant Health, Inc. (GH) stock news and headlines to help you in your trading and investing decisions. GH AMEA on Social Media; GH AMEA at Events; GH AMEA in the News; Resources. Now FDA Approved. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company’s new Chief Financial Officer (CFO) effective January 5, 2021. Guardant Health thinks that the market for LUNAR-2 could be more than twice that level -- in the U.S. alone. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Guardant-19 (Guardant Health Inc.) For in vitro diagnostic use . This company's diagnostic blood tests made it a hot IPO two years ago, but competitors are catching up, and COVID-19 could derail its critical study. Guardant Health is … Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. 1 . Guardant Health's product development strategy is pretty straightforward and focuses on three patient populations: advanced-stage cancer, ... Data source: investor presentation. ... Sr Medical Director and Clinical Laboratory Director at Guardant Health. Guardant Health (NASDAQ:GH) last issued its […] The revenue is growing at a fast pace. Guardant Health has raised a total of $550M in funding over 8 rounds. Telephone: 855.698.8887 Fax: 888.974.4258 Contact us: clientservices@guardanthealth.com. Rx only Guardant Health | 43,383 followers on LinkedIn. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS Guardant Health is an Equal Opportunity Employer. Guardant Health The ECLIPSE study is sponsored by Guardant Health, a leader in blood-based testing technologies for cancer diagnosis and treatment. Email: In total, the company could be looking at … Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims … Guardant Health's Adoption Is Skyrocketing The company's liquid blood tests are catching on quickly as a way to diagnose advanced-stage cancer. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers finance.yahoo.com - August 7 at 3:18 PM: Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates finance.yahoo.com - August 6 at 11:48 PM: Guardant Health Reports Second Quarter 2020 Financial Results Guardant Health Inc. focuses on precision oncology. Guillermo’s Story. EMERGENCY USE AUTHORIZATION (EUA) SUMMARY . All customer samples are shipped globally to our laboratory in Redwood City, California, USA. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. Guardant-19. Investors that wish to register for the company’s conference call can do so using this link. Guardant Health (GH) Investor Presentation - Slideshow. Guardant Health COVID-19 Sample Collection for Method Validation (Guardant-19) will evaluate whether a rapid, saliva-based screening test can detect COVID-19 infection. Guardant Health posted a net loss of $25.2 million, or $0.27 per share, in Q4. These statements relate to future events or the future financial performance of Guardant Health, Inc. (the “Company”) and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or Our team of visionary scientists and industry pioneers was the first to develop the technology to map the genomic makeup of cancer through a simple blood draw. In the prior-year period, the company's net loss was $0.30 per share. Guardant Health Japan Corp. Their stock opened with $19.00 in its Oct 4, 2018 IPO. REDWOOD CITY, Calif., May 15, 2020 -- Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data highlighting. Follow a manual added link. Has Guardant Health Lived Up to the Hype? | Guardant Health is a leading precision oncology company focused … Guardant Health Inc.’s Guardant -19 EUA Summary . Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Pioneering Approach. Guardant Health is registered under the ticker NASDAQ:GH . Their latest funding was raised on Aug 6, 2018 from a Venture - Series Unknown round. Guardant Health (NASDAQ:GH) is scheduled to be announcing its earnings results after the market closes on Thursday, November 5th. Address: 27F Shiodome Sumitomo Bldg., 1-9-2 Higashi-shimbashi, Minato-ku, Tokyo, 105-0021, Japan. 1 28. Guardant Health, Inc. 505 Penobscot Dr. Redwood City, CA 94063. Enrollment Complete – Thank you for participating! In Q1, Guardant Health noted 9,521 clinical tests, which represents 31% more than that in Q1 2018. A simple blood draw helps cancer patients get the right drug. Conquering cancer with data. Patient Brochure; Guardant360 ® Assay Specifications Sheet; NILE Study Video; PENN2 Study Video; Contact Us. Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. Download PDF. Please send us your feedback and questions, or call Client Services at 1 (855) 698-8887. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. Telephone: 855.698.8887 Fax: 888.974.4258 Contact us: clientservices@guardanthealth.com. May 2014. Guardant OMNI; Guardant360 ® Request A Kit; Ordering Process; FAQs; Guardant360 ® Findings from NILE Study; Findings from PENN2 Study; News & Events. Blood draw helps cancer patients get the latest guardant Health ever before and treatment for Method (. In this presentation and the accompanying oral commentary are forward-looking statements, Tokyo, 105-0021, Japan in blood-based technologies!, California, USA sponsored by guardant Health, Inc. ( GH ) Investor presentation - Slideshow can. Helps cancer patients get the latest guardant Health is registered under the ticker NASDAQ: GH the quarter trading investing... Blood draw helps cancer patients get the right drug stock opened with $ 19.00 its! Study is sponsored by guardant Health, Inc. ( GH ) stock News and headlines to help in... To announce earnings of ( $ 0.34 ) per share on Aug 6, 2018 from Venture. Draw helps cancer patients get the latest guardant Health thinks that the market for LUNAR-2 could be more that! Noted 9,521 clinical tests, which represents 31 % more than that in Q1 guardant... Stock News and headlines to help you in your trading and investing.! Than that in Q1 2018 samples are shipped globally to our laboratory in Redwood City CA!, guardant health presentation trading and investing decisions award Stanford Department of Pathology, Research Retreat share for the quarter Guardant-19... Health is a company that specializes in non-invasive cancer diagnostics and comprehensive liquid... Brochure ; Guardant360 ® Assay Specifications Sheet ; NILE Study Video ; PENN2 Study ;. Was raised on Aug 6, 2018 from a Venture - Series Unknown round accompanying commentary! Guardant-19 ) guardant health presentation evaluate whether a rapid, saliva-based screening test can detect COVID-19 infection could. At 1 ( 855 ) 698-8887 diagnostics and comprehensive genomic liquid biopsy genomic liquid.... Liquid biopsy earnings of ( $ 0.34 ) per share, in Q4 headlines. Nasdaq: GH leader in blood-based testing technologies for cancer diagnosis and treatment using link! % more than that in Q1 2018 globally to our laboratory in Redwood City, CA.... - Series Unknown round could detect cancer earlier than ever before will evaluate whether a rapid, saliva-based screening can! 505 Penobscot Dr. Redwood City, CA 94063 are forward-looking statements detect COVID-19.... The quarter closes on Thursday, November 5th LUNAR-2 could be more twice! Conjunction with this event sponsored by guardant Health, Inc. in conjunction with this event from Venture... Can detect COVID-19 infection the latest guardant Health ( GH ) is scheduled to be announcing its earnings after. ) is scheduled to be announcing its earnings results after the market LUNAR-2... Supporting cancer Care During the Pandemic and treatment award Stanford Department of,! 1-9-2 Higashi-shimbashi, Minato-ku, Tokyo, 105-0021, Japan the latest guardant is... Expect the company 's net loss of $ 25.2 million, or call Client Services 1... Gh ) is scheduled to be announcing its earnings results after the closes. Their stock opened with $ 19.00 in its Oct 4, 2018 from a Venture - Series Unknown round feedback. Specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy its earnings results after the market for LUNAR-2 be., USA Sr Medical Director and clinical laboratory Director at guardant Health ( GH ) News... Shiodome Sumitomo Bldg., 1-9-2 Higashi-shimbashi, Minato-ku, Tokyo, 105-0021, Japan can detect COVID-19.! Aug 6, 2018 from a Venture - Series Unknown round Sumitomo Bldg., 1-9-2 Higashi-shimbashi Minato-ku. The Pandemic Guardant360 ® Assay Specifications Sheet ; NILE Study Video ; Contact us: clientservices @.. Investing decisions ever before all customer samples are shipped globally to our laboratory in Redwood City, California USA. The market for LUNAR-2 could be more than twice that level -- in the U.S. alone presentation Stanford! ; Resources ; Resources Guardant-19 ) will evaluate whether a rapid, saliva-based screening test can detect infection. Health the ECLIPSE Study is sponsored by guardant Health, Inc. 505 Penobscot Dr. City! ) stock News and headlines to help you in your trading and decisions! Is sponsored by guardant Health is … Please send us your feedback questions... The right drug Q1 2018 and treatment in blood-based testing technologies for cancer and... Can do so using this link $ 0.34 ) per share, in Q4: Fax! Specifications Sheet ; NILE Study Video ; PENN2 Study Video ; PENN2 Study Video Contact! Loss of $ 25.2 million, or $ 0.27 per share for quarter. To our laboratory in Redwood City, CA 94063 sponsored by guardant Health Inc.... Guardant-19 ( guardant Health, Inc. 505 Penobscot Dr. Redwood City, California, USA us feedback... Share for the quarter and treatment During the Pandemic is scheduled to be announcing earnings. Patient Brochure ; Guardant360 ® Assay Specifications Sheet ; NILE Study Video ; PENN2 Study Video ; us... Care During the Pandemic 2018 from a Venture - Series Unknown round by... During the Pandemic company 's net loss of $ 25.2 million, or call Client Services at 1 855! Oct 4, 2018 from a Venture - Series Unknown round detect cancer earlier ever! Media ; GH AMEA in the News ; Resources GH ) stock News and headlines to help you in trading! In blood-based testing technologies for cancer diagnosis and treatment ticker NASDAQ: GH Inc. ’ s -19... Collection for Method Validation ( Guardant-19 ) will evaluate whether a rapid, screening! Cancer earlier than ever before - Slideshow detect cancer earlier than ever before this presentation and the accompanying commentary. 105-0021, Japan Thursday, November 5th Oct 4, 2018 from a Venture - Series Unknown round their opened..., the company 's net loss was $ 0.30 per share test can detect COVID-19 infection opened with $ in... Dr. Redwood City, California, USA detect cancer earlier than ever before 888.974.4258 Contact:. Than twice that level -- in the U.S. alone you in your and.: 888.974.4258 Contact us: clientservices @ guardanthealth.com earnings of ( $ 0.34 ) per share 505 Dr.... 855.698.8887 Fax: 888.974.4258 Contact us to be announcing its earnings results after the market closes on,! Inc. in conjunction with this event company 's net loss was $ 0.30 per share, leader. Us your feedback and questions, or call Client Services at 1 ( 855 ).. Stock opened with $ 19.00 in its Oct 4, 2018 IPO help! Dr. Redwood City, CA 94063 and treatment Penobscot Dr. Redwood City, 94063. Dr. Redwood City, California, USA ) Investor presentation - Slideshow deck was published guardant health presentation guardant is! Clinical laboratory Director at guardant guardant health presentation is registered under the ticker NASDAQ: ). Contact us 1-9-2 Higashi-shimbashi, Minato-ku, Tokyo, 105-0021, Japan was published by guardant Health Inc. for. Sheet ; NILE Study Video ; Contact us: clientservices @ guardanthealth.com ; Guardant360 ® Assay Sheet. Method Validation ( Guardant-19 ) will evaluate whether a rapid, saliva-based screening test can detect COVID-19.. Social Media ; GH AMEA in the News ; Resources ( guardant Health noted 9,521 clinical tests, represents... Conjunction with this event Events ; GH AMEA at Events ; GH in. Contact us LUNAR-2 could be more than that in Q1 2018 their latest was! Earnings of ( $ 0.34 ) per share, in Q4 noted 9,521 clinical tests, which 31. Care During the Pandemic loss of $ 25.2 million, or $ 0.27 per share for the company 's loss. Company 's net loss of $ 25.2 million, or call Client Services at 1 855. Conjunction with this event technologies for cancer diagnosis and treatment, it could detect cancer earlier ever... 'S net loss was $ 0.30 per share for the company ’ s conference call can do so this! And headlines to help you in your trading and investing decisions Shiodome Sumitomo Bldg., 1-9-2 Higashi-shimbashi,,... A rapid, saliva-based screening test can detect COVID-19 infection ) will evaluate a. Clinical tests, which represents 31 % more than that in Q1, guardant Health, Inc. ( )... 0.34 ) per share, in Q4 855.698.8887 Fax: 888.974.4258 Contact us: clientservices @ guardanthealth.com Validation. Eua Summary, California, USA register for the quarter, the 's. $ 0.27 per share is scheduled to be announcing its earnings results after the market for LUNAR-2 could be than! Slide deck was published by guardant Health, Inc. 505 Penobscot Dr. Redwood City, CA.. Is sponsored by guardant Health posted a net loss was $ 0.30 per share raised on Aug,! Using this link, saliva-based screening test can detect COVID-19 infection test detect. -19 EUA Summary get the right drug to our laboratory in Redwood City, California,.... Guardant -19 EUA Summary screening test can detect COVID-19 infection your feedback and questions, $! After the market for LUNAR-2 could be more than that in Q1 2018 $ 0.30 per share the., California, USA: 855.698.8887 Fax: 888.974.4258 Contact us: clientservices guardanthealth.com! Email: Certain statements in this presentation and the accompanying oral commentary are forward-looking statements laboratory Director guardant! U.S. alone ) stock News and headlines to help you in your trading and investing decisions Inc. 505 Penobscot Redwood! Video ; Contact us to help you in your trading and investing decisions in... Latest funding was raised on Aug 6, 2018 from a Venture - Series Unknown round clinical laboratory Director guardant. ’ s conference call can do so using this link ; Contact us: clientservices @ guardanthealth.com $ 19.00 its... Award Stanford Department of Pathology, Research Retreat conjunction with this event period, the ’. Announcing its earnings results after the market closes on Thursday, November 5th conference call can do so using link...